1261582-04-0

Basic information

• Product Name: 3-broMo-5-Methoxybenzoyl chloride
• Synonyms: 3-broMo-5-Methoxybenzoyl chloride
• CAS NO: 1261582-04-0
• Molecular Formula: C₈H₆BrClO₂
• Molecular Weight: 249.48904
• EINECS: -0
• Mol File: 1261582-04-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-broMo-5-Methoxybenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-broMo-5-Methoxybenzoyl chloride(1261582-04-0)
• EPA Substance Registry System: 3-broMo-5-Methoxybenzoyl chloride(1261582-04-0)

Safety Data

• Hazardous Substances Data: 1261582-04-0(Hazardous Substances Data)

Upstream product

• 157893-14-6 3-bromo-5-methoxybenzoic acid 
• 864293-44-7 2-amino-5-bromo-3-methoxy benzoic acid 
• 3177-80-8 2-amino-3-methoxybenzoic acid 

Downstream Products

• 1429129-72-5 (3-(3,5-dimethylisoxazol-4-yl)-5-hydroxyphenyl)(phenyl)methanone 
• 1509919-71-4 3-bromo-5-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol 
• 1509919-99-6 2-(3-bromo-5-methoxyphenyl)-4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidine 
• 1509919-92-9 2-(3-bromo-5-methoxyphenyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-4(3H)-one 
• 1509919-85-0 3-(3-bromo-5-methoxybenzamido)furo[2,3-b]pyridine-2-carboxamide 
• 1509919-78-1 ethyl 3-(3-bromo-5-methoxybenzamido)furo[2,3-b]pyridine-2-carboxylate 
• 1177558-45-0 3-methoxy-5-bromobenzamide 

Relevant articles and documents

Structure-Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi

Chagas disease is a neglected parasitic disease caused by the parasitic protozoan Trypanosoma cruzi and currently affects around 8 million people. Previously, 2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0227) was discovered to be a sub-micromolar inhibitor (pIC50=6.4) of T. cruzi. So far, SAR investigations of this scaffold have focused on the alkoxy substituent, the pyrazolone nitrogen substituent and the aromatic substituent of the core phenylpyrazolone. In this study, modifications of the phenyldihydropyrazolone scaffold are described. Variations were introduced by installing different substituents on the phenyl core, modifying the geminal dimethyl and installing various bio-isosteres of the dihydropyrazolone group. The anti T. cruzi activity of NPD-0227 could not be surpassed as the most potent compounds show pIC50 values of around 6.3. However, valuable additional SAR data for this interesting scaffold was obtained, and the data suggest that a scaffold hop is feasible as the pyrazolone moiety can be replaced by a oxazole or oxadiazole with minimal loss of activity.

Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors

The bromodomain protein module and histone deacetylase (HDAC), which recognize and remove acetylated lysine, respectively, have emerged as important epigenetic therapeutic targets in cancer treatments. Herein we presented a novel design approach for cancer drug development by combination of bromodomain and HDAC inhibitory activity in one molecule. The designed compounds were synthesized which showed inhibitory activity against bromodomain 4 and HDAC1. The representative dual bromodomain/HDAC inhibitors, compound 11 and 12, showed potent antiproliferative activities against human leukaemia cell line K562 and MV4-11 in cellular assays. This work may lay the foundation for developing dual bromodomain/HDAC inhibitors as potential anticancer therapeutics.

Crystal structures of PI3Kα complexed with PI103 and its derivatives: New directions for inhibitors design

The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays important roles in cell proliferation, growth, and survival. Hyperactivated PI3K is frequently found in a wide variety of human cancers, validating it as a promising target for cancer therapy. We determined the crystal structure of the human PI3Kα-PI103 complex to unravel molecular interactions. Based on the structure, substitution at the R1 position of the phenol portion of PI103 was demonstrated to improve binding affinity via forming a new H-bond with Lys802 at the bottom of the ATP catalytic site. Interestingly, the crystal structure of the PI3Kα-9d complex revealed that the flexibility of Lys802 can also induce additional space at the catalytic site for further modification. Thus, these crystal structures provide a molecular basis for the strong and specific interactions and demonstrate the important role of Lys802 in the design of novel PI3Kα inhibitors.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.